drugset / Trial / NCT02717858

A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.

NCT02717858

Phase 1 Completed 52 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the effects of liraglutide on gallbladder emptying in overweight and obese subjects.

Timeline

Start
2016-03-16
Primary completion
2017-02-27
Completion
2017-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 3 mg Subcutaneous